[go: up one dir, main page]

GB2371803A - Antibodies - Google Patents

Antibodies Download PDF

Info

Publication number
GB2371803A
GB2371803A GB0212763A GB0212763A GB2371803A GB 2371803 A GB2371803 A GB 2371803A GB 0212763 A GB0212763 A GB 0212763A GB 0212763 A GB0212763 A GB 0212763A GB 2371803 A GB2371803 A GB 2371803A
Authority
GB
United Kingdom
Prior art keywords
scfv
dam
antibodies
myers
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB0212763A
Other versions
GB0212763D0 (en
Inventor
Alan John Kingsman
Susan Mary Kingsman
Christopher Robert Bebbington
Miles William Carroll
Fiona Margaret Ellard
Kevin Alan Myers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Biomedica UK Ltd
Original Assignee
Oxford Biomedica UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Biomedica UK Ltd filed Critical Oxford Biomedica UK Ltd
Priority to GB0212763A priority Critical patent/GB2371803A/en
Priority claimed from PCT/GB1999/003859 external-priority patent/WO2000029428A2/en
Priority claimed from GB0003527A external-priority patent/GB0003527D0/en
Priority claimed from GB0005071A external-priority patent/GB0005071D0/en
Priority claimed from PCT/GB2000/004317 external-priority patent/WO2001036486A2/en
Publication of GB0212763D0 publication Critical patent/GB0212763D0/en
Publication of GB2371803A publication Critical patent/GB2371803A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The use of an ScFv Ab (ScFv Ab) capable of recognising a disease associated molecule (DAM) in the manufacture of a medicament for the prevention and/or treatment of a disease condition associated with a DAM is described. The ScFv Ab has therapeutic, diagnostic and prognostic applications.

Description

:,UK Patent Application 'g,GB ',2 371 803 PA {43) Date of Printing by UK
Office 07.08.2002 (21) Application No 0212763.7 (61) INTCL7 C12N 15/85, A61P 35/00, C07K 16/10 16/24 16/30
(22) DateofFiling 13.11.2000 (52) UK CL (Edition T) (30) Priority Data C3H HB7V HF5A H656 H675 H690 H802 H810 H840 (31) 9903859 (32) 18.11.1999 (33) GB U1S S1313
(31) 0003527 (32) 15.02.2000
(31) 0005071 (32) 02.03.2000 (56) Documents Cited by ISA WO 2000/029428 A WO 1999/045126 A
(86) International Application Data WO 1998/055607 A WO 1998/012227 A PCT/GB2000/004317 En 13.11.2000 WO 1997/042329 A WO 1989/007947 A EMBL Database Acc. No. AJ012159 (Oct.1998) - Myers (87) International Publication Data et al. WO2001/036486 En 25.05.2001 Brit. J. Cancer 1998, 78(2), pp.181-188 - Jackson et al. Immunotechnology 1996, 2(3), pp.181196 - Osbourn etl. (71) Applicant(s) J. Biol. Chem. 1994, 269(12), pp. 9319-9324 - Myers et Oxford BioMedica IUK) Limrted al. (Incorporated in the United Kingdom) Medawar Centre, Robert Robinson Avenue, (58) Field of Search by ISA
The Oxford Science Park, OXFORD, OX4 4GA, INT CL, A61 K, CO7K, GOlN United Kingdom Online: EPODOC, WPI, PAJ, BIOSIS, MEDLINE, EMBL (72) and (74) continued overleaf (54) Abstract Title Antibodies (57) The use of an ScFv Ab (ScFv Ab) capable of recognising a disease associated molecule (DAM) in the manufacture of a medicament for the prevention and/or treatment of a disease condition associated with a DAM is described. The ScFv Ab has therapeutic, diagnostic and prognostic applications.
C) W _1 o C This print does not include sequence listings that have been lodged with the International Bureau. D
(72) Inventor(s) Alan John Kingsman Susan Mary Kingsman Christopher Robert Bebbington Miles William Carroll Fiona Margaret Ellard Kevin Alan Myers (74) Agent and/or Address for Service D Young & Co 21 New Fewer Lane, LONDON, EC4A IDA, United Kingdom
GB0212763A 1999-11-18 1999-11-18 Antibodies Withdrawn GB2371803A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB0212763A GB2371803A (en) 1999-11-18 1999-11-18 Antibodies

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/GB1999/003859 WO2000029428A2 (en) 1998-11-18 1999-11-18 5t4 tumour-associated antigen for use in tumour immunotherapy
GB0212763A GB2371803A (en) 1999-11-18 1999-11-18 Antibodies
GB0003527A GB0003527D0 (en) 2000-02-15 2000-02-15 Antibodies
GB0005071A GB0005071D0 (en) 2000-03-02 2000-03-02 Antibodies
PCT/GB2000/004317 WO2001036486A2 (en) 1999-11-18 2000-11-13 Scfv antibodies against disease associated molecules

Publications (2)

Publication Number Publication Date
GB0212763D0 GB0212763D0 (en) 2002-07-10
GB2371803A true GB2371803A (en) 2002-08-07

Family

ID=27447789

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0212763A Withdrawn GB2371803A (en) 1999-11-18 1999-11-18 Antibodies

Country Status (1)

Country Link
GB (1) GB2371803A (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989007947A1 (en) * 1988-03-04 1989-09-08 Cancer Research Campaign Technology Limited Improvements relating to antigens
WO1997042329A1 (en) * 1996-05-04 1997-11-13 Zeneca Limited Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system
WO1998012227A1 (en) * 1996-09-19 1998-03-26 Diagnocure Inc. Recombinant single chain antibodies directed against the gp54 cancer marker, composition comprising same and use thereof
WO1998055607A2 (en) * 1997-06-04 1998-12-10 Oxford Biomedica (Uk) Limited Tumor targeted vector
WO1999045126A2 (en) * 1998-03-06 1999-09-10 Oxford Biomedica (Uk) Limited Enhanced prodrug activation
WO2000029428A2 (en) * 1998-11-18 2000-05-25 Oxford Biomedica (Uk) Limited 5t4 tumour-associated antigen for use in tumour immunotherapy

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989007947A1 (en) * 1988-03-04 1989-09-08 Cancer Research Campaign Technology Limited Improvements relating to antigens
WO1997042329A1 (en) * 1996-05-04 1997-11-13 Zeneca Limited Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system
WO1998012227A1 (en) * 1996-09-19 1998-03-26 Diagnocure Inc. Recombinant single chain antibodies directed against the gp54 cancer marker, composition comprising same and use thereof
WO1998055607A2 (en) * 1997-06-04 1998-12-10 Oxford Biomedica (Uk) Limited Tumor targeted vector
WO1999045126A2 (en) * 1998-03-06 1999-09-10 Oxford Biomedica (Uk) Limited Enhanced prodrug activation
WO2000029428A2 (en) * 1998-11-18 2000-05-25 Oxford Biomedica (Uk) Limited 5t4 tumour-associated antigen for use in tumour immunotherapy

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Brit. J. Cancer 1998, 78(2), pp.181-188 - Jackson et al. *
EMBL Database Acc. No. AJ012159 (Oct. 1998) - Myers et al. *
Immunotechnology 1996, 2(3), pp.181-196 - Osbourn et l. *
J. Biol. Chem. 1994, 269(12), pp.9319-9324 - Myers et al. *

Also Published As

Publication number Publication date
GB0212763D0 (en) 2002-07-10

Similar Documents

Publication Publication Date Title
Sakthi Devi et al. Applications of gold and silver nanoparticles in theranostics
Vallée et al. Curcumin and endometriosis
Khan et al. Caffeine modulates cadmium-induced oxidative stress, neuroinflammation, and cognitive impairments by regulating Nrf-2/HO-1 in vivo and in vitro
De Nigris et al. Beneficial effects of pomegranate juice on oxidation-sensitive genes and endothelial nitric oxide synthase activity at sites of perturbed shear stress
Gukovsky et al. Curcumin ameliorates ethanol and nonethanol experimental pancreatitis
Ahmed et al. Quercetin and naringenin abate diethylnitrosamine/acetylaminofluorene-induced hepatocarcinogenesis in Wistar rats: the roles of oxidative stress, inflammation and cell apoptosis
Gheorghe et al. Biomaterials for the prevention of oral candidiasis development
Song et al. Anti-colitic effects of kanjangs (fermented soy sauce and sesame sauce) in dextran sulfate sodium-induced colitis in mice
Shrestha et al. Efficient synthesis of chlorin e6 and its potential photodynamic immunotherapy in mouse melanoma by the abscopal effect
Murali et al. Enhancement of cancer chemotherapeutic efficacy of cyclophosphamide by Curculigo orchioides Gaertn and its ameliorative effects on cyclophosphamide-induced oxidative stress
Al‐Quraishy et al. Plasmodium chabaudi‐infected mice spleen response to synthesized silver nanoparticles from Indigofera oblongifolia extract
Katzengruber et al. MKK4 inhibitors—Recent development status and therapeutic potential
Opris et al. Neurobehavioral and ultrastructural changes induced by phytosynthesized silver-nanoparticle toxicity in an in vivo rat model
NO20060901L (en) New application of antisecretory factor
Michel et al. Extracts from the leaves of Campomanesia velutina inhibits production of LPS/INF-γ induced inflammatory mediators in J774A. 1 cells and exerts anti-inflammatory and antinociceptive effects in vivo
Rust et al. Burkholderia lethal factor 1, a novel anti-cancer toxin, demonstrates selective cytotoxicity in MYCN-amplified neuroblastoma cells
Yuan et al. Substance addiction rehabilitation drugs
Wigner et al. Clinical potential of fruit in bladder cancer prevention and treatment
Park et al. Topical application of 7, 3′, 4′-Trihydroxyisoflavone alleviates atopic dermatitis-like symptoms in NC/Nga mice
GB2371803A (en) Antibodies
Cai et al. Rubiadin-1-methyl ether inhibits BECN1 transcription and Beclin1-dependent autophagy during osteoclastogenesis by inhibiting NF-κB p65 activation
Bai et al. Inhibiting the aggregation of Aβ by natural product molecules
Marey et al. Fighting sepsis‐induced liver damage with biosynthesized silver nanoparticles
WO2004056768A3 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
Chung et al. The inhibitory effects of terminalia catappa l. Extract on the migration and invasion of human glioblastoma multiforme cells

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)